サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1678512

GLP-1アゴニスト減量薬の世界市場：市場規模・シェア・動向分析 (薬剤別・投与経路別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

出版日
ページ情報
英文 153 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
GLP-1アゴニスト減量薬の世界市場：市場規模・シェア・動向分析 (薬剤別・投与経路別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年02月05日
発行: Grand View Research
ページ情報: 英文 153 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

GLP-1アゴニスト減量薬市場の成長と動向：

Grand View Research社の最新レポートによると、世界のGLP-1アゴニスト減量薬の市場規模は2030年までに488億4,000万米ドルに達すると予測され、2025年から2030年までのCAGRは18.54%で成長すると予測されています。

Semaglutide（Wegovy）、Liraglutide（Saxenda）、Tirzepatide（Zepbound）などの減量治療におけるGLP-1アゴニスト（作動薬）の需要が、医療分野の大きなビジネスチャンスを促進しています。肥満や代謝状態の管理に効果的な結果を示しているこれらの医薬品は、市場の成長を牽引しています。セマグルチド（ウェゴビー）とリラグルチド（サクセンダ）はすでに信頼できる減量療法としての地位を確立しているが、ティルゼパチド（ゼップバウンド）は同クラスの他の薬剤と比較してさらに高い有効性を示し、有望な選択肢として浮上しています。これらの治療薬は、食欲を調節し、インスリン感受性を改善することで効果を発揮し、その使用を支持する臨床エビデンスが増加していることから、肥満症治療におけるGLP-1アゴニストの受容性は高まっています。

経口剤の導入は、これらの治療法をより利用しやすくするだけでなく、注射によらない治療法を好む患者層の拡大にもつながります。GLP-1アゴニストの流通において、薬局の果たす役割はますます重要になってきています。特に小売薬局は、ウェゴビーとサクセンダの処方箋を応需し、薬剤へのアクセスだけでなく、患者教育や肥満管理者への継続的なサポートを提供することで人気を集めています。便利な薬の補充やカウンセリングサービスを提供できる小売薬局は、長期的な減量管理をサポートする上で非常に重要な存在となっています。

特に患者が治療を開始し、綿密なモニタリングを必要とする場合、病院の薬局は依然として重要な役割を担っていますが、患者が長期的なケアに移行するにつれ、小売薬局はより重要な役割を担うようになってきています。病院薬局は、治療の初期段階においては医学的管理が重要であるため重要ですが、患者が安定し、治療が進むにつれて、小売薬局や専門薬局に移行することが多くなります。これらの薬局は、治療への継続的なアクセスを提供し、専門的なサービスを提供する上で重要な役割を果たしています。

専門薬局やオンライン薬局もGLP-1アゴニスト減量薬の流通に関与するようになってきています。これらの薬局は、在宅配送や個別化された服薬カウンセリングなど、患者に合わせたサービスを提供することができ、特に長期治療レジメンの患者にとって有益です。薬局の役割を拡大することで、減量療法への一貫したアクセスを必要とする患者に、さらなる利便性とサポートを提供することができます。

公衆衛生上の主要課題の一つである肥満対策への関心の高まりが、GLP-1アゴニスト減量薬産業の拡大を後押ししています。2型糖尿病、心血管疾患、睡眠時無呼吸症候群など、肥満に伴う長期的な健康リスクが認識されるにつれ、効果的な治療法に対する需要が高まっています。GLP-1受容体とGIP受容体の両方を標的とするティルゼパチドの新規作用機序は、その優れた有効性から大きな注目を集めており、GLP-1アゴニストの需要をさらに押し上げる可能性があります。

これらの薬剤の需要が高まるにつれ、特に薬剤の流通とサプライチェーン・マネジメントの分野で課題が浮上します。注射療法を常に利用できるようにするには、堅牢なコールドチェーン・ロジスティクスと、薬剤の使用を最適化するための患者教育への重点的な取り組みが必要となります。さらに、経口剤の開発は、アクセシビリティとアドヒアランスを向上させる重要な機会であり、製薬会社がより幅広い患者集団に対応するための新たな道を提供します。

GLP-1アゴニスト減量薬市場：分析概要

  • 薬剤別では、セマグルチド（wegovy）セグメントが2024年に60.70%の最大売上シェアで市場をリードし、肥満管理に好ましい治療オプションとしての地位を固めました。セマグルチドは、体重を大幅に減少させ、代謝の健康を改善する効果が実証されており、臨床的に受け入れられつつあることから、このクラスの治療薬として市場をリードしています。
  • 投与経路別では、非経口剤が2024年の売上高シェア92.7％で市場をリードしています。これらの注射療法は、毎週または隔週で投与され、長期的な体重減少を促進し、インスリン抵抗性のような基礎代謝状態に対処する効果が実証されているため、好まれています。
  • 流通チャネル別では、小売薬局セグメントが2024年に55.46%の最大売上シェアで市場をリードしました。小売薬局が提供する利便性とアクセシビリティの向上により、小売薬局は減量薬を使用する患者の主要なアクセスポイントとなっています。
  • 北米が2024年に最大の市場シェアを占めたのは、医療インフラが整備されていること、神経疾患に対する認知度が高いこと、高度な治療オプションが利用可能であることなどの要因によるものです。同地域は研究とイノベーションに力を入れており、市場の成長をさらに後押ししています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 GLP-1アゴニスト減量薬市場：変動要因・傾向・範囲

  • 親市場の見通し
  • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • GLP-1アゴニスト減量薬市場：分析ツール
    • ポーターの分析
    • PESTEL分析

第4章 GLP-1アゴニスト減量薬市場：薬剤別の推定・動向分析

  • GLP-1アゴニスト減量薬市場：セグメントダッシュボード、薬剤別
  • GLP-1アゴニスト減量薬市場：変動分析、薬剤別 (2024年・2030年)
  • セマグルチド（Wegovy）
  • リラグルチド（Saxenda）
  • ティルゼパタイド（Zepbound）
  • その他の薬物

第5章 GLP-1アゴニスト減量薬市場： 投与経路別の推定・動向分析

  • GLP-1アゴニスト減量薬市場：セグメントダッシュボード、投与経路別
  • GLP-1アゴニスト減量薬市場：変動分析、投与経路別 (2024年・2030年)
  • 非経口
  • 経口

第6章 GLP-1アゴニスト減量薬市場：流通チャネルの推定・動向分析

  • GLP-1アゴニスト減量薬市場：セグメントダッシュボード、流通チャネル別
  • GLP-1アゴニスト減量薬市場：流通チャネル変動分析 (2024年・2030年)
  • 病院薬局
  • 小売薬局
  • その他の薬局

第7章 GLP-1アゴニスト減量薬市場：地域別の推定・動向分析

  • GLP-1アゴニスト減量薬の市場シェア：地域別 (2024年・2030年)
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート
    • 南アフリカ

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業市場シェア分析（2024年）
  • 企業ヒートマップ分析（2024年）
  • 企業プロファイル
    • Eli Lilly and Company.
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Viking Therapeutics
    • Structure Therapeutics
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 4 Global GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 Global GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 8 North America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 11 U.S. GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 14 Canada GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 17 Mexico GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 21 Europe GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 24 Germany GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Germany GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 27 UK GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 UK GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 30 France GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 France GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 33 Italy GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Italy GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 36 Spain GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 Spain GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 39 Denmark GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Denmark GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 42 Sweden GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 45 Norway GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Norway GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 52 China GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 China GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 55 Japan GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Japan GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 58 India GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 India GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 61 South Korea GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 64 Australia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 67 Thailand GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 71 Latin America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 74 Brazil GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 77 Argentina GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 84 South Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 90 UAE GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 UAE GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 93 Kuwait GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Kuwait GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 GLP-1 Agonists Weight Loss Drugs, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five forces Analysis
  • Fig. 14 Global GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis
  • Fig. 15 Global GLP-1 Agonists Weight Loss Drugs Market, for Semaglutide (Wegovy), 2018 - 2030 (USD Million)
  • Fig. 16 Global GLP-1 Agonists Weight Loss Drugs Market, for Liraglutide (Saxenda), 2018 - 2030 (USD Million)
  • Fig. 17 Global GLP-1 Agonists Weight Loss Drugs Market, for Tirzepatide (Zepbound), 2018 - 2030 (USD Million)
  • Fig. 18 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Drugs, 2018 - 2030 (USD Million)
  • Fig. 19 Global GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analys
  • Fig. 20 Global GLP-1 Agonists Weight Loss Drugs Market, for Parenteral 2018 - 2030 (USD Million)
  • Fig. 21 Global GLP-1 Agonists Weight Loss Drugs Market, for Oral, 2018 - 2030 (USD Million)
  • Fig. 22 Global GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis
  • Fig. 23 Global GLP-1 Agonists Weight Loss Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 24 Global GLP-1 Agonists Weight Loss Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 25 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways GLP-1 Agonists Weight Loss Drugs Market, Region 2018 -
  • Fig. 27 Regional Outlook, 2022 & 2030 GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 Global GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 29 North America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 US GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 UK GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 France GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 China GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 India GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Company/Competition Categorization
  • Fig. 58 Company Market Share Analysis, 2024
  • Fig. 59 Company Market Position Analysis, 2024
  • Fig. 60 Strategy Mapping
目次
Product Code: GVR-4-68040-512-4

GLP-1 Agonists Weight Loss Drugs Market Growth & Trends:

The global GLP-1 agonists weight loss drugs market size is anticipated to reach USD 48.84 billion by 2030 and is projected to grow at a CAGR of 18.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for GLP-1 Agonists in weight loss treatments, including Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is fueling significant opportunities in the healthcare sector. These drugs, which have shown effective results in managing obesity and metabolic conditions, are driving market growth. Semaglutide (Wegovy) and Liraglutide (Saxenda) have already established themselves as reliable weight loss therapies, while Tirzepatide (Zepbound) is emerging as a promising option, showing even greater efficacy compared to other drugs in its class. These therapies work by regulating appetite and improving insulin sensitivity, and with growing clinical evidence supporting their use, the acceptance of GLP-1 Agonists in obesity management is increasing.

The introduction of oral versions would not only make these therapies more accessible but also broaden the patient base who prefer non-injection-based therapies. Pharmacies are playing an increasingly important role in the distribution of GLP-1 Agonists. Retail pharmacies, in particular, are gaining traction in fulfilling prescriptions for Wegovy and Saxenda, providing not only access to the medications but also patient education and ongoing support for those managing obesity. Retail pharmacies' ability to offer convenient medication refills and counseling services makes them crucial in supporting the long-term management of weight loss.

While hospital pharmacies are still key players, especially when patients start treatment and require close monitoring, retail pharmacies are taking on a more significant role as patients transition to long-term care. Hospital pharmacies are important during the initial stages of therapy, where medical supervision is critical, but as patients stabilize and progress with treatment, they often shift to retail or specialty pharmacies. These pharmacies play a vital role in providing continued access to therapy and offering specialized services.

Specialty pharmacies and online pharmacies are also becoming more involved in the distribution of GLP-1 Agonists weight loss drugs. These pharmacies can offer tailored services, such as home delivery and personalized medication counseling, which can be particularly beneficial for patients on long-term treatment regimens. By expanding their role, they provide added convenience and support for patients needing consistent access to weight loss therapies.

The growing focus on combating obesity, one of the leading public health challenges, is driving the expansion of the GLP-1 agonists weight loss drug industry. With increasing recognition of the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and sleep apnea, there is a rising demand for effective treatments. Tirzepatide's novel mechanism of action, which targets both GLP-1 and GIP receptors, is attracting considerable attention for its superior efficacy and could further boost demand for GLP-1 Agonists.

As the demand for these medications rises, challenges will emerge, particularly in the areas of drug distribution and supply chain management. Ensuring that injectable therapies are consistently available will require robust cold chain logistics and increased focus on patient education to optimize the use of the drugs. Moreover, the development of oral formulations represents a significant opportunity to improve accessibility and adherence, providing a new avenue for pharmaceutical companies to cater to a broader patient population.

GLP-1 Agonists Weight Loss Drugs Market Report Highlights:

  • Based on drug, the semaglutide (wegovy) segment led the market with the largest revenue share of 60.70% in 2024, solidifying its position as the preferred treatment option for obesity management. Semaglutide's proven efficacy in significantly reducing body weight and improving metabolic health, and its growing clinical acceptance make it the leading therapy in this class.
  • Based on route of administration, the parenteral segment led the market with the largest revenue share of 92.7% in 2024. These injectable therapies, administered either weekly or bi-weekly, are preferred due to their proven effectiveness in promoting long-term weight loss and addressing underlying metabolic conditions like insulin resistance.
  • Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using weight loss medications.
  • North America accounted for the largest market share in 2024, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 Agonists Weight Loss Drugs Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of obesity
      • 3.3.1.2. Increasing adoption of weight loss drug therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. High cost of treatment
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
  • 3.4. GLP-1 Agonists Weight Loss Drugs Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. GLP-1 Agonists Weight Loss Drugs Market: By Drug Estimates & Trend Analysis

  • 4.1. GLP-1 Agonists Weight Loss Drugs Market: Drug Segment Dashboard
  • 4.2. GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Semaglutide (Wegovy)
    • 4.3.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Liraglutide (Saxenda)
    • 4.4.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tirzepatide (Zepbound)
    • 4.5.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Drugs
    • 4.6.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Estimates & Trend Analysis

  • 5.1. GLP-1 Agonists Weight Loss Drugs Market: Route of Administration Segment Dashboard
  • 5.2. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Parenteral
    • 5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Segment Dashboard
  • 6.2. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other Pharmacies
    • 6.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. GLP-1 Agonists Weight Loss Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. GLP-1 Agonists Weight Loss Drugs Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Eli Lilly and Company.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Viking Therapeutics
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Structure Therapeutics
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives